Immunocore Holdings plc Stock-Based Compensation
Immunocore Holdings plc (IMCR) reported Stock-Based Compensation of $15.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Immunocore Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.40M, a 6.27% decline year-over-year.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.30M, a 33.59% decline year-over-year.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.34M, a 3.78% decline year-over-year.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.84M, a 49.98% increase year-over-year.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for fiscal 2025 was $37.70M, a 10.26% increase from fiscal 2024.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for fiscal 2024 was $34.19M, a 5.30% increase from fiscal 2023.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for fiscal 2023 was $32.47M, a 1.27% decline from fiscal 2022.
- Immunocore Holdings plc share-based payment arrangement, noncash expense for fiscal 2022 was $32.89M, a 32.74% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.71M 10-Q · filed 2026-08-06 | $24.05M derived: sum of 3 quarters · filed 2026-08-06 | $33.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.30M 10-Q · filed 2026-05-06 | $14.64M derived: sum of 2 quarters · filed 2026-05-06 | $24.48M derived: sum of 3 quarters · filed 2026-05-06 | $34.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.18M derived: sum of 2 quarters · filed 2026-02-25 | $28.21M derived: sum of 3 quarters · filed 2026-08-06 | $37.70M 10-K · filed 2026-02-25 |
| 2025-09-30 | $9.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.87M derived: sum of 2 quarters · filed 2026-08-06 | $29.36M 10-Q · filed 2025-11-06 | $38.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $19.52M 10-Q · filed 2026-08-06 | $28.19M derived: sum of 3 quarters · filed 2026-08-06 | $34.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.49M 10-Q · filed 2026-05-06 | $18.16M derived: sum of 2 quarters · filed 2026-05-06 | $24.71M derived: sum of 3 quarters · filed 2026-05-06 | $34.72M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.23M derived: sum of 2 quarters · filed 2026-02-25 | $25.23M derived: sum of 3 quarters · filed 2026-02-25 | $34.19M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $16.56M derived: sum of 2 quarters · filed 2025-11-06 | $25.52M 10-Q · filed 2025-11-06 | $32.71M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.96M 10-Q · filed 2025-08-07 | $26.16M derived: sum of 3 quarters · filed 2026-02-25 | $34.35M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $8.96M 10-Q · filed 2025-05-07 | $16.16M derived: sum of 2 quarters · filed 2026-02-25 | $24.35M derived: sum of 3 quarters · filed 2026-02-25 | $33.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.39M derived: sum of 2 quarters · filed 2026-02-25 | $24.21M derived: sum of 3 quarters · filed 2026-02-25 | $32.47M 10-K · filed 2026-02-25 |
| 2023-09-30 | $8.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $17.02M derived: sum of 2 quarters · filed 2024-11-06 | $25.28M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $8.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $17.08M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $8.26M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $32.89M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $48.89M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |